Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
复制标题
低剂量白细胞介素 2 联合或不联合中脉冲剂量白细胞介素 2 治疗的缓解后治疗对于老年急性髓性白血病患者的耐受性良好:癌症和白血病 B 组研究 9420。
DOI:
--
复制
发表时间:
2002
期刊:
影响因子:
--
通讯作者:
Caligiuri,MichaelA
中科院分区:
文献类型:
--
作者:
Farag,SherifS;George,StephenL;Lee,EdwardJ;Baer,Maria;Dodge,RichardK;Becknell,Brian;Fehniger,ToddA;Silverman,LewisR;Crawford,Jeffrey;Bloomfield,ClaraD;Larson,RichardA;Schiffer,CharlesA;Caligiuri,MichaelA
登录
查看更多内容
影响因子:
2.6
作者:
Savary,CA;Lotzova,E
通讯作者:
Lotzova,E
影响因子:
56.9
作者:
Bauer, S;Groh, V;Spies, T
通讯作者:
Spies, T
影响因子:
12.8
作者:
P. Wiernik;J. Dutcher;M. Todd;G. Caliendo;L. Benson
通讯作者:
L. Benson
影响因子:
20.3
作者:
K. Oshimi;Y. Oshimi;M. Akutsu;Y. Takei;H. Saito;M. Okada;H. Mizoguchi
通讯作者:
H. Mizoguchi
影响因子:
11.4
作者:
Johnson,CS;Thurlow,SM;Furmanski,P
通讯作者:
Furmanski,P